Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Investing.com -- RBC Capital Markets raised its price target on Biogen (NASDAQ: BIIB) to $213 from $205, pointing to a broad set of advancing pipeline programs that could unlock as much as 40% ...

Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Additional programs include BIIB080, a tau-targeting therapy for Alzheimer’s, and zorevunersen, currently in Phase 3 for Dravet syndrome. RBC also highlighted upcoming data for dapirolizumab pegol, ...

A high-level overview of Stoke Therapeutics, Inc. (STOK) stock. View (STOK) real-time stock price, chart, news, analysis, analyst reviews and more.

STOK is presently in phase 3 trials with zorevunersen, a treatment for Dravet Syndrome. DS is a very difficult and debilitating epileptic disorder which occurs in approximately 1 in 16,000 births ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, which Biogen says is the underlying cause of most cases of Dravet syndrome, and is on the brink of ...